Biodexa Pharmaceuticals PLC is a GB-based company operating in Biotechnology industry. The company is headquartered in Abingdon, Oxfordshire and currently employs 13 full-time employees. The company went IPO on 2014-12-08. Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company. The firm is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.
Follow-Up Questions
Qui est le CEO de Biodexa Pharmaceuticals PLC ?
Mr. Stephen Stamp est le Chief Executive Officer de Biodexa Pharmaceuticals PLC, il a rejoint l'entreprise depuis 2019.
Quelle est la performance du prix de l'action BDRX ?
Le prix actuel de BDRX est de $6.6, il a increased de 1.34% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Biodexa Pharmaceuticals PLC ?
Biodexa Pharmaceuticals PLC appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de Biodexa Pharmaceuticals PLC ?
La capitalisation boursière actuelle de Biodexa Pharmaceuticals PLC est de $4.0M
Est-ce que Biodexa Pharmaceuticals PLC est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 3 analystes ont établi des notations d'analystes pour Biodexa Pharmaceuticals PLC, y compris 3 achat fort, 3 achat, 1 maintien, 0 vente et 3 vente forte
